Le Lézard
Classified in: Health
Subject: PDT

InventHelp Inventor Develops Aid for Men with Urinary Incontinence (ROH-457)


PITTSBURGH, March 14, 2018 /PRNewswire/ -- "Having experienced urinary incontinence, I can attest to how aggravating it can be to deal with," said an inventor from Batavia, N.Y. "The clamp used now is uncomfortable, and surgery is invasive and expensive. For these reasons, I came up with a better alternative."

InventHelp Logo (PRNewsfoto/InventHelp)

He created a prototype for the DEVICE TO HELP INCONTINENT MEN to offer a solution for male urinary incontinence. The unit prevents urine from leaking from the urethra. This stops underwear and pants from being stained by urine. The accessory eliminates the need to wear diapers or pads. It helps the user to deal with incontinence without having to resort to expensive surgery. Moreover, the unit features a comfortable, non-invasive design.

The original design was submitted to the Rochester office of InventHelp. It is currently patent pending and available for licensing or sale to manufacturers or marketers. For more information, write Dept. 16-ROH-457, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

 

SOURCE InventHelp


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: